These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 26276734)

  • 61. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
    Goda JS; Lewis S; Agarwal A; Epari S; Churi S; Padmavati A; Gupta T; Shetty P; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2015 Aug; 135():46-53. PubMed ID: 26038275
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
    Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
    J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
    Joo JD; Kim H; Kim YH; Han JH; Kim CY
    J Korean Med Sci; 2015 Nov; 30(11):1597-603. PubMed ID: 26539003
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.
    Mao Y; Yao Y; Zhang LW; Lu YC; Chen ZP; Zhang JM; Qi ST; You C; Wang RZ; Yang SY; Zhang X; Wang JS; Chen JX; Yang QY; Shen H; Li ZY; Wang X; Ma WB; Yang XJ; Zhen HN; Zhou LF
    Chin Med J (Engl); 2015 Oct; 128(20):2751-8. PubMed ID: 26481741
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combined modality treatment of newly diagnosed glioblastoma multiforme in a regional neurosurgical centre.
    Gauden AJ; Hunn A; Erasmus A; Waites P; Dubey A; Gauden SJ
    J Clin Neurosci; 2009 Sep; 16(9):1174-9. PubMed ID: 19540125
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
    Minniti G; Lanzetta G; Scaringi C; Caporello P; Salvati M; Arcella A; De Sanctis V; Giangaspero F; Enrici RM
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):93-9. PubMed ID: 22079725
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Survival Analysis of Glioblastoma Multiforme.
    Witthayanuwat S; Pesee M; Supaadirek C; Supakalin N; Thamronganantasakul K; Krusun S
    Asian Pac J Cancer Prev; 2018 Sep; 19(9):2613-2617. PubMed ID: 30256068
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis.
    Welzel G; Gehweiler J; Brehmer S; Appelt JU; von Deimling A; Seiz-Rosenhagen M; Schmiedek P; Wenz F; Giordano FA
    J Neurooncol; 2015 Sep; 124(2):265-73. PubMed ID: 26045360
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic factors in patients with glioblastoma multiforme: focus on the pathologic variants.
    Alimohammadi E; Bagheri SR; Sadeghsalehi A; Rizevandi P; Rezaie Z; Abdi A
    Acta Neurol Belg; 2020 Dec; 120(6):1341-1350. PubMed ID: 31222512
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6767-71. PubMed ID: 16203762
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients.
    Zur I; Tzuk-Shina T; Guriel M; Eran A; Kaidar-Person O
    Sci Rep; 2020 Jun; 10(1):9595. PubMed ID: 32533126
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interdisciplinary treatment of glioblastoma: analysis of prognostic factors and treatment results in unselected patients.
    Langsenlehner T; Groll MJ; Quehenberger F; Payer F; Mokry M; Kapp KS
    Neoplasma; 2012; 59(6):662-8. PubMed ID: 22862166
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Recurrence Pattern Analysis of Primary Glioblastoma.
    Rapp M; Baernreuther J; Turowski B; Steiger HJ; Sabel M; Kamp MA
    World Neurosurg; 2017 Jul; 103():733-740. PubMed ID: 28434963
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?
    Nakamura H; Murakami R; Hirai T; Kitajima M; Yamashita Y
    Acta Radiol; 2013 Mar; 54(2):214-20. PubMed ID: 23138021
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution.
    Hulshof MC; Koot RW; Schimmel EC; Dekker F; Bosch DA; González González D
    Strahlenther Onkol; 2001 Jun; 177(6):283-90. PubMed ID: 11446316
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
    Wen J; Chen W; Zhu Y; Zhang P
    BMC Cancer; 2021 Jan; 21(1):81. PubMed ID: 33468109
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
    Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
    Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.